A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...

A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and — due to innovations in manufacturing — could make future cellular ...

In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of ...

T cell-based immunotherapies, including CAR-T cell therapies, have significantly advanced treatment options for lymphomas such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

Sanofi NCT01421667 A study of brentuximab vedotin in relapsed or refractory non-Hodgkin lymphoma Seattle Genetics, Inc. NCT01786135 A safety study of SGN-CD19A for B-cell lymphoma Seattle Genetics ...

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

Researchers have developed a new microscopic method to observe the interactions of therapeutic antibodies with target molecules on tumor cells.

Meanwhile, the Phase 2 EPCORE® NHL-1 trial evaluating epcoritamab monotherapy in relapsed or refractory large B-cell lymphoma ...

A new type of off-the-shelf cell-based immunotherapy shows promise for B-cell lymphomas, and could make make future cellular ...

A phase 1 clinical trial co-led by researchers at WashU Medicine found that a new type of cell-based immunotherapy was safe for patients with several types of B-cell lymphoma, a type of blood cancer.